Antipsychotic Effects of Pimozide in Schizophrenia: Treatment Response Prediction with Acute Dextroamphetamine Response

Archives of General Psychiatry

Volumn 39, Issue 3, 1982, Pages 261-266

  van Kammen, Daniël P ^a   Docherty, John P ^a   Marder, Stephen R ^a,b   Schulz, S Charles ^a,c   Dalton, Lynne ^a   Bunney, William E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Veterans Administration Hospital   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; LITHIUM CARBONATE; PIMOZIDE; PLACEBO;

CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METHODOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; SCHIZOPHRENIA; THERAPY;

ADOLESCENT; ADULT; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIMOZIDE; PROGNOSIS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0020085373     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1982.04290030011002     Document Type: Article

References (49)

1. Van Kammen DP, Bunney WE Jr, Docherty JP, et al: Amphetamineinduced catecholamine activation in schizophrenia and depression: Behavioral and physiological effects, in Costa E, Gessa GL (eds): Advances in Biochemical Psycho-pharmacology. New York, Raven Press, 1975, vol 16, pp 655–659.
2. Segal DS, Janowsky DS: Psychostimulant-induced behavioral effects: Possible models of schizophrenia, in Lipton MA, Di Mascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1113–1123.
3. Schube PG, McManamy MC, Trapp CE, et al: The effect of benzedrine sulphate on certain abnormal mental states. Am J Psychiatry 1937;94: 27–32.
4. Anderson EW: Further observations on benzedrine. Br Med J 1938;2: 60–64.
5. Davidoff E, Reifenstein EC: The results of 18 months of benzedrine sulfate therapy in psychiatry. Am J Psychiatry 1939;95: 945–969.
6. Belart W: Pathogenetisches und Therapeutisches aus Pervitinversuchen bei Schizophrenia. Schweiz Med Wochenschr 1942;2: 41–42.
7. Simon JL, Taube H: A preliminary study on the use of methedrine in psychiatric diagnosis. J Nerv Ment Dis 1946;104: 593–596.
8. Bischoff A: Ueber eine therapeutische Verwendung der sogenannten ‘Weck-Amine’ in der Behandlung schizophrener Erregungszustände. Psychiatr Neurol 1951;121: 329–344.
9. Hope JM, Callaway E, Sands SL: Intravenous pervitin and the psychopathology of schizophrenia. Dis Nerv Syst 1951;12: 67–72.
10. Pennes MH: Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate and d-lysergic acid diethylamide (LSD25). J Nerv Ment Dis 1954;119: 95–112.
11. Kiloh LG, Neilson M, Andrews G: Response of depressed patients to methylamphetamine. Br J Psychiatry 1974;125: 496–499.
12. Janowsky DA, Davis JM: Methylphenidate, dextroamphetamine, and levamphetamine. Arch Gen Psychiatry 1976;33: 304–308.
13. Kornetsky C: Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry 1976;33: 1425–1428.
14. Angrist B, Rotrosen J, Gershon S: Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 1980;67: 31–38.
15. Van Kammen DP, Bunney WE Jr, Docherty JP, et al: d-Amphetamine induces heterogeneous changes in psychotic behavior of schizophrenic patients. Am J Psychiatry, to be published.
16. Van Kammen DP, Docherty JP, Marder SR, et al: Lack of behavioral supersensitivity to d-amphetamine administration following pimozide withdrawal in schizophrenic patients. Arch Gen Psychiatry 1980;37: 287–290.
17. Van Kammen DP, Docherty JP, Marder SR, et al: Chronic pimozide pretreatment differentially affects responses to d-amphetamine in schizophrenia. Arch Gen Psychiatry, to be published.
18. Crow TJ: Molecular pathology of schizophrenia: More than one disease process? Br Med J 1980;280: 66–68.
19. Van Kammen DP, Docherty JP, Bunney WE Jr: Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry, to be published.
20. Snyder SH: The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry 1976;133: 197–202.
21. Meltzer HY, Stahl SM: The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 1976;2: 19–76.
22. Carlsson A: Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 1978;135: 164–173.
23. Van Kammen DP: The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 1979;4: 37–46.
24. Seeman P, Lee T: Antipsychotic drugs: Direct correlation between clinical potency and presynaptic actions on dopamine neurons. Science 1975;188: 1217–1219.
25. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science 1976;192: 481–483.
26. Van der Velde CD: Variability in schizophrenia. Arch Gen Psychiatry 1976;33: 489–496.
27. Linn WM, Caffey EM, Klett CJ, et al: Day treatment and psychotropic drugs in the after-care of schizophrenic patients. Arch Gen Psychiatry 1979;36: 1055–1066.
28. Hogarty GE, Schooler NR, Ulrich R, et al: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36: 1283–1294.
29. Fawcett J, Siomopoulos V: Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Arch Gen Psychiatry 1971;25: 244–247.
30. Maas JW, Fawcett JA, Dekirmenjian H: Catecholamine metabolism, depressive illness and drug response: Arch Gen Psychiatry 1972;26: 252–262.
31. Van Kammen DP, Murphy DL: Prediction of imipramine antidepressant response by a one-day d-amphetamine trial. Am J Psychiatry 1978;135: 1179–1183.
32. Van Kammen DP, Murphy DL: Prediction of antidepressant response to lithium carbonate by a one-day administration of d-amphetamine in unipolar depressed women. Neuropsychobiology 1979;5: 266–273.
33. Pinder RM, Brogden RN, Sawyer RP, et al: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976;12: 1–40.
34. Denef C, van Neuten JM, Leysen JE, et al: Evidence that pimozide is not a partial agonist of dopamine receptors. Life Sci 1979;25: 217–226.
35. Kessler KA, Waletzky JP: Clinical use of the antipsychotics. Am J Psychiatry 1981;138: 202–209.
36. Van Kammen DP, Docherty JP, Marder SR, et al: Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients. Psychiatry Res 1981;4: 313–325.
37. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria. New York, New York State Department of Mental Hygiene, New York Psychiatric Institute, 1978.
38. Carpenter WT, Strauss JS, Bartko JJ: Flexible system for the diagnosis of schizophrenia: Report from the WHO International Pilot Study of Schizophrenia. Science 1973;182: 1275–1278.
39. Phillips L: Case history data and prognosis in schizophrenia. J Nerv Ment Dis 1953;117: 515–525.
40. Overall JE, Hollister LE, Pichot P: Major psychiatric disorders: A four-dimensional model. Arch Gen Psychiatry 1967;16: 146–151.
41. Bunney WE Jr, Hamburg DA: Methods for reliable observation of behavior. Arch Gen Psychiatry 1963;9: 280–294.
42. Hocking RR: The analysis and selection of variables in linear regression. Biometrics 1976;32: 1–50.
43. Ellinwood EH Jr: Amphetamine psychosis: Individuals, settings and sequences, in Ellinwood EH Jr, Cohen S (eds): Current Concepts on Amphetamine Abuse, US Dept of Health, Education, and Welfare, publication 72–9085. US Dept of Health, Education, and Welfare, 1972.
44. Seeman P, Lee T, Bird ED, et al: Elevation of brain neuroleptic/dopamine receptors in schizophrenia, in Baxter C, Melnechuk (eds): Perspectives in Schizophrenia Research. New York, Raven Press, 1980, pp 195–207.
45. Cross AJ, Crow TJ, Owen F: 3H-flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 1981;74: 122–124.
46. Johnstone EC, Frith CD, Crow TJ, et al: Mechanism of antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1: 848–851.
47. Marder SR, van Kammen DP, Docherty JP, et al: Predicting drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatry 1979;36: 1080–1085.
48. Zander KJ, Fischer B, Zimmer R, et al: Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology 1981;73: 43–47.
49. Docherty JP, van Kammen DP, Siris SG, et al: Stages of onset of schizophrenic psychosis. Am J Psychiatry 1978;135: 420–426.